

(d) Remarks

Claims 8-16 have been cancelled and replaced by new claims 17-19.

Support for new claim 17 is found at Examples 1 and 2; support for claim 18, Examples 5, 7, 16 and 17; and support for claim 19, Examples 16 and 17. Consideration of the claims is expressly requested. Applicants submit that no new matter has been added.

Former claims 8-16 were rejected under Rule 112, second paragraph. This rejection is deemed moot and should be withdrawn due to the cancellation of claims 8-16.

Former claims 8-16 were rejected as anticipated by Onikubo '859. Former claims 8, 10, 11, 13 and 15 were rejected as anticipated by Nakatsuka '933. Former claims 8-16 were also rejected as obvious over Hosokawa '966 or Onikubo '859. Finally, former claims 8-13 and 15 were rejected as obvious over Nakatsuka '933. The rejections have been rendered moot by the cancellation of claims 8-16.

New claim 17 is characterized by the present compounds 40a or 71b. Compound 40a is an oligomer with three fluorenylene repeating units and is terminated at each end by a N-tolyl, N-phenanthryl amino group. Compound 71b is an oligomer with four fluorenylene repeating groups and is terminated at each end by a N-tolyl-N-anthryl amino group. The references of record fail to teach or suggest such compounds.

It is noted that compound F-42 in paragraph [0076] on page 47 of the Nakatsuka '933 Translation is a fluorenylene oligomer with three repeating units, but with no anthryl or phenanthryl substitution on each terminal amino group.

Wherefore, the claims should be allowed and the case passed to issue.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,



Peter Saxon
Peter Saxon
Attorney for Applicants
Registration No. 24,947

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

NY_MAIN 614673v1